See the DrugPatentWatch profile for rystiggo
Rystiggo is a medication containing the active ingredient 4-aminopyridine [1]. It is used to treat Lambert-Moni Syndrome.
What is Lambert-Moni Syndrome?
Lambert-Moni Syndrome is a rare autoimmune disorder that affects the neuromuscular junction, leading to muscle weakness [1].
How does Rystiggo work?
Rystiggo, or 4-aminopyridine, works by blocking potassium channels in nerve cells. This blockage helps to improve the transmission of nerve signals to muscles, thereby reducing muscle weakness [1].
When did Rystiggo become available?
Rystiggo was approved by the U.S. Food and Drug Administration (FDA) in 2023 [2].
Are there other treatments for Lambert-Moni Syndrome?
Other treatments may include other medications aimed at improving neuromuscular transmission or suppressing the immune system. Specific treatment plans are determined by a healthcare professional based on the individual patient's needs [1].
What are the potential side effects of Rystiggo?
Common side effects of Rystiggo can include urinary tract infections, upper respiratory tract infections, headache, nausea, diarrhea, and pain in the arms or legs [1].
What is the patent status of Rystiggo?
Information regarding the patent status of Rystiggo can be found on DrugPatentWatch.com [3].
Sources:
- DrugPatentWatch.com
- DrugPatentWatch.com
- DrugPatentWatch.com